- Home
- SNDX vs TRS Comparison
SNDX vs TRS Comparison
Compare SNDX & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- TRS
- Stock Information
- Founded
- SNDX 2005
- TRS 1986
- Country
- SNDX United States
- TRS United States
- Employees
- SNDX N/A
- TRS N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- TRS Industrial Specialties
- Sector
- SNDX Health Care
- TRS Industrials
- Exchange
- SNDX Nasdaq
- TRS Nasdaq
- Market Cap
- SNDX 1.1B
- TRS 1.0B
- IPO Year
- SNDX 2016
- TRS 2007
- Fundamental
- Price
- SNDX $9.92
- TRS $35.73
- Analyst Decision
- SNDX Strong Buy
- TRS Strong Buy
- Analyst Count
- SNDX 11
- TRS 1
- Target Price
- SNDX $34.00
- TRS $45.00
- AVG Volume (30 Days)
- SNDX 1.7M
- TRS 412.7K
- Earning Date
- SNDX 08-04-2025
- TRS 07-29-2025
- Dividend Yield
- SNDX N/A
- TRS 0.45%
- EPS Growth
- SNDX N/A
- TRS N/A
- EPS
- SNDX N/A
- TRS 0.91
- Revenue
- SNDX $43,722,000.00
- TRS $973,840,000.00
- Revenue This Year
- SNDX $431.08
- TRS $6.37
- Revenue Next Year
- SNDX $105.38
- TRS $5.49
- P/E Ratio
- SNDX N/A
- TRS $39.29
- Revenue Growth
- SNDX N/A
- TRS 6.72
- 52 Week Low
- SNDX $8.58
- TRS $19.33
- 52 Week High
- SNDX $23.37
- TRS $36.77
- Technical
- Relative Strength Index (RSI)
- SNDX 51.66
- TRS 87.71
- Support Level
- SNDX $9.42
- TRS $29.93
- Resistance Level
- SNDX $10.75
- TRS $36.77
- Average True Range (ATR)
- SNDX 0.58
- TRS 1.03
- MACD
- SNDX 0.08
- TRS 0.47
- Stochastic Oscillator
- SNDX 51.74
- TRS 86.49
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About TRS TriMas Corporation
TriMas Corp designs, develops and manufactures a diverse set of products primarily for the consumer products, aerospace & defense, and industrial markets . The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.